# Questions the Class Map Answers > Research Peptide FAQ: Ipamorelin, GHK-Cu, PT-141, Tirzepatide — Peptide Broker — Direct answers on research peptide fundamentals — what ipamorelin, GHK-Cu, PT-141 and tirzepatide are, how each class works, what the risks are and how far the published evidence goes, with citations throughout. **RESEARCH PEPTIDE FUNDAMENTALS / FAQ** Short, citation-anchored answers to the questions readers most often bring to these four peptide classes. ## Do all peptides work the same way? No, and this is the single most common misconception about the category. A peptide is a short chain of amino acids; that is a description of chemistry, not of function. The four peptides briefed on this desk act on four unrelated systems: the pituitary growth hormone axis, gut incretin receptors, central melanocortin receptors, and the extracellular matrix of skin. Their evidence bases, regulatory statuses and risk profiles have essentially nothing in common. Class — meaning which receptor or tissue a molecule engages — is the useful unit of comparison. The word ‘peptide' is not. ## What is ipamorelin? Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed from the earlier compound GHRP-1 by removing the central Ala-Trp dipeptide. It is a selective agonist of the ghrelin / growth hormone secretagogue receptor, GHS-R1a, on pituitary somatotrophs, and it triggers a discrete pulse of growth hormone release. Its defining feature is selectivity: unlike GHRP-6 and GHRP-2, it does not meaningfully raise ACTH, cortisol or prolactin. It is not approved as a drug in any jurisdiction and is prohibited in sport at all times. ## What does ipamorelin do for you? The honest answer is that the published human record does not support a claim about what it does for anyone. The only Phase 2 randomised controlled trial — 114 adults after bowel resection, given 0.03 mg/kg intravenously twice daily for up to seven days — missed its primary endpoint, with a median time to first tolerated meal of 25.3 hours against 32.6 hours on placebo (p=0.15) [3]. What is well established is narrower: a human pharmacokinetic study showed a single discrete growth hormone pulse peaking about forty minutes after dosing, with a terminal half-life of roughly two hours [4]. In rats, fifteen days of subcutaneous dosing raised longitudinal bone growth rate without changing total IGF-1 or bone turnover markers [5]. Community reports of better sleep and faster recovery are anecdotal, not clinical evidence. ## What are the risks of ipamorelin? The documented cautions follow from what growth hormone does rather than from the peptide itself. Growth hormone stimulates hepatic IGF-1, a well-characterised mitogen, which makes active or recent malignancy the first flagged concern. It reduces peripheral insulin sensitivity and can raise fasting glucose, making impaired glucose tolerance a second. It promotes sodium and water retention, making cardiovascular disease, heart failure and oedema a third — a concern reinforced by a 28-day study of a different GHS-R1a agonist that found dose-dependent myocardial degeneration in rats [2]. Ghrelin-receptor agonists also activate hypothalamic appetite centres. Above all, long-term human safety is uncharacterised: no Phase 3 trial exists, and most circulating material is research-grade of unverified purity. ## What does a GHK-Cu peptide do? GHK-Cu signals tissue repair. At picomolar-to-nanomolar concentrations it stimulates dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and decorin, and rebalances matrix metalloproteinases against their TIMP inhibitors — pushing tissue toward building rather than breaking down. The copper ion enables lysyl-oxidase cross-linking of collagen and elastin and supports superoxide-dismutase-like antioxidant activity. In one review, procollagen synthesis increased in 70% of GHK-Cu-treated subjects, against 50% for vitamin C and 40% for retinoic acid [6][9]. ## What is GHK-Cu and how does it work? GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine chelated one-to-one to a copper(II) ion, with the copper held through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen. The GHK sequence occurs naturally within the alpha-2(I) chain of type I collagen and in SPARC/osteonectin, and plasma levels fall from roughly 200 ng/mL at age twenty to about 80 ng/mL by sixty [9]. It works as both a copper chaperone and a broad signalling molecule: gene-expression analysis reports it altering expression of approximately 31.2% of human genes at a fifty-percent-or-greater change threshold, with 59% increased and 41% suppressed, including strong stimulation of the ubiquitin-proteasome system at 41 genes up against 1 down [7]. ## Is GHK-Cu peptide really anti-aging? The mechanistic case is genuinely substantial and the clinical case is genuinely small, and both statements are true at once. On the mechanism side there is quantified matrix synthesis, measured skin permeation of 136.2 plus or minus 17.5 micrograms per square centimetre of copper over forty-eight hours [10], and broad gene-expression effects [7]. On the clinical side, human evidence is limited to small topical dermatology trials and a single 45-patient trial of a combination formulation for hair growth [8]. A substantial share of the foundational literature originates with one investigator and colleagues, so independent replication of the broader claims is limited, and the widely quoted ‘4,000 genes' figure conflates the verified 31.2% statistic with broader-threshold extrapolation. Depth of mechanism is not the same as depth of outcome evidence. ## What is the difference between GHK and GHK-Cu? GHK is the free tripeptide; GHK-Cu is the same tripeptide bound to a copper(II) ion. The distinction is not cosmetic. Copper coordination is required for most of the reported bioactivities — the plain peptide without copper does not reproduce key effects such as stimulation of MMP-2 in cell studies. Intact GHK-Cu also binds copper very tightly, which is what prevents the copper from acting as a pro-oxidant; if the complex degrades or is stripped by a low-pH active, that protective binding is lost. Because the two are frequently conflated in the literature, the form used in a given study determines what the study is evidence for. ## What is PT-141? PT-141 is a synthetic cyclic heptapeptide lactam analogue of alpha-melanocyte-stimulating hormone, with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It is an agonist at melanocortin receptors, chiefly MC4R with additional MC3R activity, which are expressed primarily in the central nervous system [17]. Under the name bremelanotide it is an approved prescription medicine in the United States for acquired, generalised hypoactive sexual desire disorder in premenopausal women, with a labelled 1.75 mg subcutaneous as-needed dose [15]. Material sold as ‘PT-141 research chemical' sits outside that approval and carries no verification of identity or purity. ## What is PT-141 used for? Its approved use is acquired, generalised hypoactive sexual desire disorder in premenopausal women; it is not approved for men, for postmenopausal women, or to enhance sexual performance [15]. In the two identical Phase 3 trials that supported that approval, enrolling 1,267 premenopausal women, it produced a statistically significant improvement in sexual desire, with an integrated FSFI-desire change of +0.35 (P<.001), and a reduction in desire-related distress of -0.33 on the relevant item (P<.001) over twenty-four weeks [13]. Independent re-analyses have argued those effects, while significant, are clinically small — an unresolved dispute worth knowing about. ## How does PT-141 differ from erectile dysfunction pills? It acts on a different organ. PDE-5 inhibitors work peripherally on vascular smooth muscle and address the mechanics of arousal. PT-141 works centrally, stimulating MC4R in hypothalamic circuits such as the medial preoptic area and engaging dopaminergic pathways governing sexual motivation. In a crossover functional-MRI study of 31 premenopausal women with hypoactive sexual desire disorder, MC4R agonism increased sexual desire for up to twenty-four hours and altered brain processing of erotic stimuli, with enhanced amygdala-insula connectivity [12]. In female rats it selectively stimulated appetitive solicitational behaviours without affecting lordosis, pacing or general motor activity [16]. It does not act through the hypothalamic-pituitary-gonadal axis and does not directly raise testosterone. ## What is tirzepatide? Tirzepatide is a linear 39-amino-acid synthetic peptide based on the native sequence of glucose-dependent insulinotropic polypeptide, carrying a C20 fatty diacid attached to a lysine side chain through a glutamic acid linker and two AEEA units. That fatty-diacid arm confers high albumin affinity and a long half-life, which is what makes once-weekly dosing feasible. It is the first approved dual agonist of the GIP and GLP-1 receptors, cleared in May 2022 for type 2 diabetes mellitus, with later approvals covering chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity [19]. ## How does tirzepatide work? It activates both the GIP receptor and the GLP-1 receptor with a single molecule. Engaging both enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite and food intake, producing larger glycaemic and weight effects in trials than selective GLP-1 receptor agonism alone. The glucose-dependence of the insulin effect is why hypoglycaemia risk is low with the drug alone and rises when it is combined with a sulfonylurea or insulin. In a 40-week trial in 1,879 adults with type 2 diabetes, it reduced glycated haemoglobin by an estimated 2.01, 2.24 and 2.30 percentage points at 5, 10 and 15 mg against 1.86 percentage points with semaglutide 1 mg [22]. ## What is tirzepatide used for? Its approved indications are type 2 diabetes mellitus [19] and, subsequently, chronic weight management and moderate-to-severe obstructive sleep apnoea in adults with obesity. The obesity evidence is the largest in this briefing: in a 72-week Phase 3 trial of 2,539 adults with obesity and without diabetes, mean weight change at week 72 was -15.0% at 5 mg, -19.5% at 10 mg and -20.9% at 15 mg, against -3.1% with placebo [21]. In an open-label head-to-head of 751 adults, least-squares mean weight change was -20.2% with tirzepatide against -13.7% with semaglutide (P<0.001) [18]. ## Which of these four has the strongest human evidence? Tirzepatide, by a wide margin — multiple 72-week Phase 3 randomised trials [21][18], a 40-week diabetes trial [22], and a dedicated safety meta-analysis of nine trials totalling 9,871 participants [20]. PT-141 is second: two identical Phase 3 trials in 1,267 women plus a 52-week open-label extension in 684 [13][14]. GHK-Cu has a large mechanistic literature but a clinical record limited to small topical studies and one 45-patient combination trial [8]. Ipamorelin is last, with a single published Phase 2 trial that missed its primary endpoint [3]. This ranks confidence, not merit — a cosmetic ingredient is not failing by lacking an outcome trial it was never required to run. ## Are these compounds safe? Safety is not a property a compound has in isolation, and the four here differ too much for one answer. Tirzepatide has the best-characterised profile precisely because it has been studied most: predominantly gastrointestinal adverse events during dose escalation [21][22], a boxed warning on thyroid C-cell tumours from rodent data, no significant pancreatitis signal but a significantly increased risk of gallbladder or biliary disease, relative risk 1.97, 95% CI 1.14 to 3.42 [20]. Bremelanotide's known profile includes nausea at 40.4%, flushing at 20.6% and headache at 12.0% over long-term use [14], plus transient blood-pressure increase and a contraindication in uncontrolled hypertension [15]. Topical Copper Tripeptide-1 has a long cosmetic safety record, while injectable GHK-Cu is unapproved and unstudied in humans. Ipamorelin's long-term human safety is simply unknown. This desk describes what the literature reports and recommends nothing to anyone. --- Peptide Broker brokers information, not product: a class-by-class digest of the published peptide literature, with no pharmacy behind it and no dose recommended to anyone.